The FDA approved a refillable ranibizumab implant for DME, offering a less frequent treatment alternative to monthly injections. A case series suggested a potential link between semaglutide and ...
Please provide your email address to receive an email when new articles are posted on . At 2 years, 74% of Black patients and 66.4% of white patients who received ranibizumab achieved vision of 20/40 ...
– Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in wet AMD, the leading cause of vision loss in people over the age of 60 – – With two refills per ...
Credit: Genentech. Susvimo is indicated for intravitreal use via the Susvimo ocular implant. For patients with diabetic retinopathy, refills of Susvimo are administered every 36 weeks (approximately 9 ...
– Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months – – Susvimo’s innovative technology via ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results